Pharmaceutical composition having bicyclic nitrogen-containing aromatic heterocyclic amide compound as active component

A composition and compound technology are applied in the field of pharmaceutical compositions using bicyclic nitrogen-containing aromatic heterocyclic amide compounds as active ingredients, and can solve the problem of no cancer treatment and the like

Inactive Publication Date: 2017-08-29
ASTELLAS PHARMA INC
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no specific description in this document that the teaching is useful for cancer treatment, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition having bicyclic nitrogen-containing aromatic heterocyclic amide compound as active component
  • Pharmaceutical composition having bicyclic nitrogen-containing aromatic heterocyclic amide compound as active component
  • Pharmaceutical composition having bicyclic nitrogen-containing aromatic heterocyclic amide compound as active component

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0105] The production methods of Compound A, Compound B, Compound C, and Compound D will be described in detail below based on examples. In addition, the production methods of these raw material compounds are shown in the production examples. In addition, the production methods of compound A, compound B, compound C and compound D are not limited to the production methods of the specific examples shown below, and other combinations of these production methods or methods obvious to those skilled in the art can also be used. to manufacture.

[0106] In this specification, naming software such as ACD / Name (registered trademark, Advanced Chemistry Development, Inc.) may be used for naming compounds.

[0107] In addition, the concentration mol / l is expressed as M for convenience. For example, a 1M aqueous sodium hydroxide solution refers to a 1 mol / l aqueous sodium hydroxide solution.

[0108] Powder X-ray diffraction using RINT-TTRII (RIGAKU company), vacuum tube: Cu, tube curre...

manufacture example 1

[0111] In 5-bromo-1H-benzimidazole-2-carboxylic acid (1.0g), 1-[4-(trifluoromethyl)benzyl]piperazine (1.0g), 1-hydroxybenzotriazole (840mg) Add N-[3-(dimethylamino)propyl]-N'-ethylcarbodiimide hydrochloride to the mixture of N,N-dimethylformamide (10ml, hereinafter abbreviated as DMF) (1.2 g), stirred overnight at room temperature. Saturated aqueous sodium bicarbonate solution was added to the reaction mixture, stirred at room temperature for 1 hour, and the resulting solid was collected by filtration and dried under reduced pressure. The obtained solid was dissolved in a mixture of chloroform (100 ml) and ethanol (1 ml) under heating to reflux. After cooling the mixture to room temperature, hexane (100ml) was added. After the resulting solid was collected by filtration and dried under reduced pressure, (5-bromo-1H-benzimidazol-2-yl){4-[4-(trifluoromethyl)benzyl]piperazine was obtained as a solid -1-yl}methanone (1.4 g).

manufacture example 2

[0113] (5-Bromo-1H-benzimidazol-2-yl){4-[4-(trifluoromethyl)benzyl]piperazin-1-yl}methanone (1.2g), 4-(4, 4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylic acid tert-butyl ester (1.6g), tetra (Triphenylphosphine) palladium (590mg), sodium carbonate (2.2g), di A mixture of alkanes (40ml) and water (10ml) was stirred at 95°C under an argon atmosphere for 24 hours, and then naturally cooled to room temperature. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, the desiccant was removed, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform-methanol) to obtain 4-[2-({4-[4-(trifluoromethyl)benzyl]piperazin-1-yl}carbonyl) as an oily substance -1H-benzimidazol-5-yl]-3,6-dihydropyridine-1(2H)-carboxylic acid tert-butyl ester (1.2 g).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a pharmaceutical composition for treating lung cancer involving mitochondrial Complex I, particularly non-small cell lung cancer. After investigating compounds having a mitochondrial Complex I inhibitory effect, the present inventor completed the present invention by confirming that the bicyclic nitrogen-containing aromatic heterocyclic amide compounds of the present invention have a mitochondrial Complex I inhibitory effect, and that these compounds have an antitumor effect on mice carrying cancer derived from non-small cell lung cancer.

Description

technical field [0001] The invention relates to a pharmaceutical composition for the treatment of lung cancer related to mitochondrial complex I, especially non-small cell lung cancer, which is effective with a bicyclic nitrogen-containing aromatic heterocyclic amide compound or a pharmaceutically acceptable salt thereof Element. Background technique [0002] Lung cancer is caused by the loss of normal function and disordered proliferation of cells in the trachea, bronchi, and alveoli. The number of deaths due to lung cancer accounts for 17% of all cancer deaths, which is the largest. About 1.3 million people die of lung cancer every year in the world . [0003] Treatments for lung cancer are broadly classified into surgery (surgical therapy), anticancer agents (chemotherapy), and radiation exposure (radiotherapy), and whether the treatment works depends on the histological type. For example, the diagnosis of lung cancer is carried out through the cytopathological diagnosi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/496A61K31/497A61P35/00A61P43/00C07D401/14
CPCC07D401/14A61K31/497A61K31/496A61P11/00A61P35/00A61P43/00A61K31/4184A61K31/454
Inventor 长岛建之
Owner ASTELLAS PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap